Nebenwirkungen · Pepaxti
Pepaxti 20 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-148671 · Präparat HOS-099940
Thrombocytopenia Thrombocytopenia was reported in 83% of patients, Grade 3/4 thrombocytopenia was reported in 74% of patients treated with Pepaxti. 33% of patients experienced Grade 3/4 thrombocytopenia during the first treatment cycle. Median time to onset of Grade 3 or 4 thrombocytopenia was 43 days from first dose. Grade 3/4 thrombocytopenia resulted in dose delay, dose reduction and dose discontinuation of Pepaxti in 41%, 23% and 12%, respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-13T15:58:00Z · SHA-256 0337d583dd185cf1f39713f18e0b459ae24ea14f440ceb8b7019b5a8f4c5f8a6 · Passage 0170a054ede42de4440246afc5dd01ab89af40c9f902b8c9eac6a6e2feff6a01 · Zeichen 5049–5505 im Abschnitt